Home / Resources / Pharma Annual R&D Review 2024 Supplement Infographic: New Active Substances Launched During 2023

Pharma Annual R&D Review 2024 Supplement Infographic: New Active Substances Launched During 2023

Infographic
Clinical
Infographic Banner for Pharma R&D Annual Review 2024 Supplement NAS Infograpic

Last year was pharma’s second-hottest ever in terms of new active substances (NASs) introduced. While the forecast for NAS launches is generally fair, there are a few clouds on the horizon.

View related products
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape
Professional using a laptop device to access Trialtrove for trial insights and strategy.
Trialtrove
The go-to resource for informing clinical trial strategy, design and execution
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline

Related resources

Citeline subscribers accessing the 2023 Deal-Making Roundup white paper reported by Biomedtracker.
MAR 28, 2024
White paper
Commercial

2023 Deal-making Roundup

An overview of alliance, M&A, and financing deal activity across the
worldwide biopharma, medical device, and in vitro diagnostics
industries in 2023

''
Clinical

Pharma R&D Annual Review 2024

For over 30 years, the Pharma R&D Annual Review has tracked how the climate is shifting. Browse our resources to help you navigate the climate.

Ingredients for a Deal-Rich Year Infographic banner
APR 23, 2024
Infographic
Clinical

Ingredients for a Deal-rich Year

The global biopharma industry is poised for a deal-rich year, thanks to a variety of factors, including growing momentum in bolt-on M&A activity.

View All Resources